Xencor, Inc. (NASDAQ:XNCR) Director Kurt A. Gustafson Sells 2,993 Shares

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) Director Kurt A. Gustafson sold 2,993 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the transaction, the director now owns 20,183 shares of the company's stock, valued at $186,087.26. This trade represents a 12.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Xencor Stock Up 0.6%

Shares of XNCR stock traded up $0.05 during mid-day trading on Thursday, hitting $8.36. The stock had a trading volume of 835,269 shares, compared to its average volume of 667,672. Xencor, Inc. has a 12-month low of $7.16 and a 12-month high of $27.24. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.89 and a quick ratio of 5.89. The firm's 50-day moving average is $9.07 and its two-hundred day moving average is $14.70. The firm has a market capitalization of $594.98 million, a P/E ratio of -2.73 and a beta of 0.87.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 181.17% and a negative return on equity of 31.94%. The business had revenue of $32.73 million for the quarter, compared to analysts' expectations of $23.44 million. During the same period in the previous year, the business earned ($1.11) earnings per share. The business's quarterly revenue was up 104.6% compared to the same quarter last year. On average, analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on XNCR. Wall Street Zen downgraded Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Wells Fargo & Company lowered their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Wedbush restated an "outperform" rating and issued a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. Barclays reduced their price target on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research note on Thursday, May 8th. Finally, William Blair initiated coverage on shares of Xencor in a report on Monday, April 21st. They set an "outperform" rating for the company. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $28.00.

Institutional Trading of Xencor

Several hedge funds have recently modified their holdings of XNCR. Sterling Capital Management LLC grew its holdings in Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 1,040 shares during the last quarter. New York State Teachers Retirement System raised its position in Xencor by 2.1% during the 1st quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company's stock worth $631,000 after buying an additional 1,200 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in Xencor by 22.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock valued at $162,000 after acquiring an additional 1,282 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of Xencor by 49.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,337 shares during the last quarter. Finally, Sanctuary Advisors LLC boosted its holdings in shares of Xencor by 5.3% in the 4th quarter. Sanctuary Advisors LLC now owns 28,263 shares of the biopharmaceutical company's stock valued at $649,000 after acquiring an additional 1,432 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.